A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors

Investigational New Drugs

Volumn 28, Issue 4, 2010, Pages 509-515

  Traynor, Anne M ^a   Gordon, Michael S ^b   Alberti, Dona ^a   Mendelson, David S ^b   Munsey, Mark S ^c   Wilding, George ^a   Gammans, Richard E ^c   Read, William L ^d  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Premiere Oncology of Arizona   (United States)

^c MediciNova Inc   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Angiogenesis; Pathologic neovascularization; Phase I; Vascular disrupting agent

Indexed keywords

DENIBULIN; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; MN-029; TUBULIN MODULATOR;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; CELLULITIS; CLINICAL ARTICLE; COUGHING; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; FLANK PAIN; HEADACHE; HEMATURIA; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VOMITING; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; DRUG RESISTANCE; MIDDLE AGED; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TUBULIN MODULATORS;

EID: 77956624019     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9264-2     Document Type: Article

References (22)

1. Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423-435. doi:10.1038/nrc1628 (Pubitemid 40791485)
2. Horsman MR, Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66:11520-11539. doi:10.1158/0008-5472. CAN-06-2848
3. Hinnen P, Eskens FA (2007) Vascular disrupting agents in clinical development. Br J Cancer 96:1159-1165. doi:10.1038/sj. bjc.6603694
4. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427. doi:10.1158/1078-0432. CCR-0642-03
5. Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B, Hill SA (2008) Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol 81: S12-S20. doi:10.1259/bjr/36205483
6. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21:2815-2822. doi:10.1200/JCO.2003.05.185 (Pubitemid 46621828)
7. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:4428-4438. doi:10.1200/JCO.2003.12. 986 (Pubitemid 46621821)
8. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416
9. LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, DeLuca PA, Evelhoch JL, Boerner SA, Wheeler C (2008) Phase I clinical evaluation of ZD6126, a novel vasculartargeting agent, in patients with solid tumors. Invest New Drugs 26:159-167. doi:10.1007/s10637-008-9112-9
10. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE (2006) Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491-1498. doi:10.1200/JCO.2005.02.7458 (Pubitemid 46638769)
11. van Heeckeren WJ, Bhakta S, Ortiz J, Duerk J, Cooney MM, Dowlati A, McCrae K, Remick SC (2006) Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol 24:1485-1488. doi:10.1200/JCO.2005.04.8801 (Pubitemid 46638767)
12. Shi W, Siemann DW (2005) Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Res 25:3899-3904
13. Ricart AD, Cooney M, Sarantopoulos J, Brell J, Locke KW, Gammans RE, Medina G, Zambito A, Tolcher AW, Remick SC (2006) A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors. J Clin Oncol 24: June 20 Suppl; abstr 3096
14. Gould S, Westwood FR, Curwen JO, Ashton SE, Roberts DW, Lovick SC, Ryan AJ (2007) Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats. J Natl Cancer Inst 99:1724-1728. doi:10.1093/jnci/ djm202 (Pubitemid 351767216)
15. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ (2006) Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24:1363-1369. doi:10.1200/JCO.2005.02.0503 (Pubitemid 46621999)
16. Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Ricart AD, Olszanski S, Spano KJ (2008) Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J Clin Oncol 26: May 20 suppl; abstr 3543
17. Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM (2006) Augmentation of radiation response with the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 64:1458-1465. doi:10.1016/j.ijrobp. 2005.11.017
18. Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S (2004) Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin. Clin Cancer Res 10:7671-7676. doi: 10.1158/1078-0432. CCR-04-1171
19. Ng QS, Goh V, Carnell D, Meer K, Padhani AR, Saunders MI, Hoskin PJ (2007) Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 67:1375-1380. doi:10.1016/j.ijrobp. 2006.11.028
20. Hamstra DA, Rehemtulla A, Ross BD (2007) Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 25:4104-4109. doi:10.1200/JCO. 2007.11.9610 (Pubitemid 47495868)
21. O'Connor JP, Jackson A, Asselin MC, Buckley DL, Parker GJ, Jayson GC (2008) Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol 9:766-776. doi:10.1016/S1470-2045 (08) 70196-7
22. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH (2008) Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 14:1407-1412. doi:10.1158/1078-0432. CCR-07-1154